Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 23Terminated 7Recruiting 3Not yet recruiting 3Active not recruiting 3Unknown 2

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Small Cell Lung Carcinoma 8Neuroblastoma 5Rhabdoid Tumor 3Ovarian Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1SCLC 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Fallopian Tube Mucinous Adenocarcinoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × Topotecan × Clear all
NCT06619236 2026-06-02

RAINFOL-02

Genmab

Phase 3 Active not recruiting
448 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡